News

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...
Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure.
Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...
The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...
Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.
Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
Dr Reddy's reported Rs 1,417 crore net profit in Q1 FY26, driven by new launches and price hikes; firm outlines global ...
The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, ...
Older adults and women using Wegovy for obesity management may be more likely to lose lean mass, although increasing protein intake may help protect against lean mass loss, according to a speaker.